Literature DB >> 1751523

Interaction of positively-charged liposomes with blood: implications for their application in vivo.

J H Senior1, K R Trimble, R Maskiewicz.   

Abstract

Liposomes with positively-charged lipid components have previously demonstrated efficacy in animal models for human diseases, and are currently being evaluated in human clinical studies. Cationic lipids can improve entrapment efficiency of drugs and other substances which are negatively charged, and facilitate penetration of biological membranes in vitro, e.g. in transfection. However, toxic effects have also been reported for positively-charged liposomes containing stearylamine. In this report we have examined gross interactions between plasma components or erythrocytes with cholesterol-rich SUV composed of PC or DPPC and having 0-50 mol% of phospholipid replaced with positively-charged stearylamine, DOTMA, or BisHOP. Plasma interactions observed included increased turbidity of the usually clear stroma and/or formation of a clot-like mass. At plasma concentrations of 0.25 mumol/ml or more, the extent of plasma interactions depended upon the concentration of positive charge, the charge density of cationic lipid initially present in the liposomes, and to a lesser degree, the nature of the lipid providing the positive charge. At liposomal positive charge concentrations of greater than 0.5 mumol/ml plasma, stearylamine provoked a strong increase in plasma turbidity, whereas liposomes incorporating DOTMA or BisHOP provoked a strong clotting response. Some hemolysis of erythrocytes in vitro occurred on interaction with cationic liposomes where positive charge was contributed by DOTMA or stearylamine, but not BisHOP. Implications for the clinical use of liposomes containing cationic lipids, is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751523     DOI: 10.1016/0005-2736(91)90160-a

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

Review 1.  Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection.

Authors:  Crispin R Dass
Journal:  J Mol Med (Berl)       Date:  2004-06-23       Impact factor: 4.599

Review 2.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

3.  Characterization and in vivo testing of a heterogeneous cationic lipid-DNA formulation.

Authors:  J G Smith; T Wedeking; J H Vernachio; H Way; R W Niven
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

4.  Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo.

Authors:  Okhil K Nag; Vivek R Yadav; Andria Hedrick; Vibhudutta Awasthi
Journal:  Int J Pharm       Date:  2013-02-16       Impact factor: 5.875

Review 5.  Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.

Authors:  Alvin J Mukalel; Rachel S Riley; Rui Zhang; Michael J Mitchell
Journal:  Cancer Lett       Date:  2019-05-14       Impact factor: 8.679

6.  Preferential binding of polyethylene glycol-coated liposomes containing a novel cationic lipid, TRX-20, to human subendthelial cells via chondroitin sulfate.

Authors:  T Harigai; M Kondo; M Isozaki; H Kasukawa; H Hagiwara; H Uchiyama; J Kimura
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

7.  Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres.

Authors:  J L Cleland; A J Jones
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

8.  Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride.

Authors:  H Heiati; N C Phillips; R Tawashi
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

9.  Effect of composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortus.

Authors:  A I Vitas; R Díaz; C Gamazo
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.